Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708419 | 0.87 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL26160014 | 0.80 | — | — | |
| SCHEMBL25492990 | 0.73 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL25795538 | 0.69 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL27269211 | 0.69 | MAPK1 (0.36) | MAPK1 | |
| SCHEMBL1709280 | 0.68 | MAPK1 (0.41) | MAPK1GRNSORT1 | |
| SCHEMBL1709291 | 0.68 | MAPK1 (0.41) | MAPK1GRNSORT1 | |
| SCHEMBL14374875 | 0.64 | MAPK1 (0.38) | MAPK1GRNSORT1 | |
| SCHEMBL179208 | 0.62 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL13632327 | 0.62 | MAPK1 (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209369-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-02-29 | — | — | US | disclosed |
| US-20230332147-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | BANK OF AMERICA, N.A. | 2023-09-14 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| US-20230126233-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126881-A1 | Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125933-A1 | MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20170369872-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| US-20170226507-A1 | COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170204411-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20150011614-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20120316220-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287424-A1 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | MTREX, RNASEH1, RNASE1 | MAPK1 4811/4885GRN 1807/4885SORT1 2134/4885 |
| US-20120316220-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | MTREX, STING1, AGO2 | MAPK1 2836/4885GRN 1834/4885SORT1 3128/4885 |
| US-20240067972-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | DPP4, DPP3, DPP7 | MAPK1 4702/4885GRN 2509/4885SORT1 1266/4885 |
| US-12018260-B2 | Tunable Reversir™ compounds | SNRPE, PLK1, LDLR | MAPK1 3310/4885GRN 119/4885SORT1 1512/4885 |
| US-20230126233-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | LRRK2, EIF2AK2, HIPK2 | MAPK1 1593/4885GRN 254/4885SORT1 3457/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | MAPK1 4476/4885GRN 3266/4885SORT1 1391/4885 |
| US-20240209374-A1 | iRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN | CHI3L1, CHIA, CHI3L2 | MAPK1 4097/4885GRN 101/4885SORT1 1063/4885 |
| US-20170204411-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | MTREX, STING1, AGO2 | MAPK1 2836/4885GRN 1834/4885SORT1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.